These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21555361)

  • 1. Anthracycline-induced cardiomyopathy in siblings with early breast cancer.
    Young AC; Mercer B; Perren TJ; Dodwell D
    Ann Oncol; 2011 Jul; 22(7):1692. PubMed ID: 21555361
    [No Abstract]   [Full Text] [Related]  

  • 2. A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer.
    Zhou Y; Ouyang T; Xie Y; Wang T; Fan Z; He Y; Lu A; Liu Y; Li J
    Breast Cancer Res Treat; 2016 Jun; 157(3):527-34. PubMed ID: 27250001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
    Del Mastro L; Levaggi A; Michelotti A; Cavazzini G; Adami F; Scotto T; Piras M; Danese S; Garrone O; Durando A; Accortanzo V; Bighin C; Miglietta L; Pastorino S; Pronzato P; Castiglione F; Landucci E; Conte P; Bruzzi P
    Breast Cancer Res Treat; 2016 Jan; 155(1):117-26. PubMed ID: 26661403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: a randomised study in advanced breast cancer.
    Riccardi A; Giordano M; Brugnatelli S; Ucci G; Danova M; Mora O; Fava S; Ascari E
    Eur J Cancer; 1995; 31A(9):1549-51. PubMed ID: 7577090
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer.
    Jones SE; Mennel RG; Peters GN; Westrick MA; Brooks BD; Knox SM; McGuffey P
    Invest New Drugs; 1988 Sep; 6(3):195-8. PubMed ID: 2847991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.
    Nagel GA; Beyer JH; Holtkamp W; Emrich D; Kneba M; Luig H; Marschner N; Rauschning W; Unger C; Wander HE
    Onkologie; 1988 Dec; 11(6):287-8. PubMed ID: 3071764
    [No Abstract]   [Full Text] [Related]  

  • 11. 5-Fluorouracil, epirubicin and cyclophosphamide (FEC combination) in advanced breast cancer.
    Zamagni C; Martoni A; Ercolino L; Baroni M; Tanneberger S; Pannuti F
    J Chemother; 1991 Apr; 3(2):126-9. PubMed ID: 1875232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
    Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
    Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
    Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
    Eur J Cancer; 1992; 29A(1):37-43. PubMed ID: 1445744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced alopecia: A novel observation.
    Rossi A; Fortuna MC; Caro G; Pigliacelli F; D'Arino A; Carlesimo M
    Australas J Dermatol; 2019 Feb; 60(1):e61-e62. PubMed ID: 29741222
    [No Abstract]   [Full Text] [Related]  

  • 17. Herpes simplex encephalitis as a complication of adjuvant chemotherapy treatment for breast cancer.
    Cathomas R; Pelosi E; Smart J; Murray N; Simmonds P
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):292-3. PubMed ID: 15997927
    [No Abstract]   [Full Text] [Related]  

  • 18. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
    Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
    Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of epirubicin in advanced breast cancer.
    Conte PF; Gennari A; Landucci E; Orlandini C
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S46-51. PubMed ID: 11970749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.